Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug

J Nucl Med. 2022 Nov;63(11):1642-1643. doi: 10.2967/jnumed.122.264299. Epub 2022 Jul 7.

¹ Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland; [email protected].
² Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
³ Division of Oncology 1, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland; and.
⁴ Division of Biometrics I, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Publication types